STAAR Surgical (STAA) Projected to Post Quarterly Earnings on Tuesday

STAAR Surgical (NASDAQ:STAA) is expected to post its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect STAAR Surgical to post earnings of $0.14 per share and revenue of $75.5370 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 17, 2026 at 12:00 AM ET.

STAAR Surgical Trading Down 4.8%

STAAR Surgical stock opened at $18.04 on Tuesday. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $30.81. The company has a market capitalization of $897.35 million, a price-to-earnings ratio of -9.25 and a beta of 1.00. The business’s fifty day simple moving average is $23.00 and its two-hundred day simple moving average is $24.84.

Wall Street Analyst Weigh In

STAA has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of STAAR Surgical in a research note on Thursday, January 22nd. Jefferies Financial Group dropped their target price on shares of STAAR Surgical from $28.00 to $21.50 and set a “buy” rating on the stock in a research note on Wednesday, January 28th. Wells Fargo & Company boosted their price objective on shares of STAAR Surgical from $28.00 to $30.75 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, January 6th. Finally, BTIG Research reissued a “neutral” rating on shares of STAAR Surgical in a report on Tuesday, January 6th. One analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $20.78.

Insider Buying and Selling

In related news, major shareholder Broadwood Partners, L.P. bought 27,485 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was acquired at an average cost of $22.05 per share, for a total transaction of $606,044.25. Following the purchase, the insider owned 15,453,629 shares in the company, valued at approximately $340,752,519.45. This represents a 0.18% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders have purchased 1,934,138 shares of company stock valued at $50,485,791. Insiders own 0.59% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its stake in shares of STAAR Surgical by 2,605.1% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 1,016 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of STAAR Surgical by 375.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 4,673 shares during the last quarter. Russell Investments Group Ltd. grew its position in STAAR Surgical by 9,928.9% during the third quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier’s stock valued at $121,000 after buying an additional 4,468 shares during the period. CIBC Bancorp USA Inc. bought a new stake in STAAR Surgical during the third quarter valued at approximately $208,000. Finally, Amundi purchased a new stake in STAAR Surgical during the third quarter valued at approximately $251,000. Institutional investors own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.